Evidence map›Paper›PMID 33072188›Full record

Trial reportCardiovascular therapeutics2020

The Effect of Early Treatment with Intravenous Magnesium Sulfate on the Incidence of Cardiac Comorbidities in Hospitalized Stroke Patients.

Kameron Bechler, Kristina Shkirkova, Jeffrey L Saver, Sidney Starkman, Scott Hamilton, David S Liebeskind, Marc Eckstein, Samuel Stratton, Frank Pratt, Robin Conwit and 1 more

Open access · goldAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Kameron BechlerKeck School of Medicine, USA.
Kristina ShkirkovaZilkha Neurogenetic Institute, University of Southern California, USA.ORCID https://orcid.org/0000-0002-9288-4258
Jeffrey L SaverStroke Center and Department of Neurology, University of California, Los Angeles, USA.
Sidney StarkmanStroke Center and Department of Neurology, University of California, Los Angeles, USA.
Scott HamiltonStanford University, USA.
David S LiebeskindStroke Center and Department of Neurology, University of California, Los Angeles, USA.
Marc EcksteinDepartment of Neurology, University of Southern California, USA.
Samuel StrattonStroke Center and Department of Neurology, University of California, Los Angeles, USA.
Frank PrattStroke Center and Department of Neurology, University of California, Los Angeles, USA.
Robin ConwitDivision of Extramural Research, NIH/NINDS, USA.
Nerses SanossianKeck School of Medicine, USA.
University of California, Los Angeles · USUniversity of Southern California · USKeck Graduate Institute · USOffice of Extramural Research · USStanford University · US

Funding

Field Administration of Stroke Therapy-Magnesium Trial (FAST-MAG)U01NS044364 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SAVER, JEFFREY L · 2003 to 2013
$46.4M
NINDS NIH HHS U01 NS044364
6 · The paper itself

Abstract

backgroundCardiac adverse events are common among patients presenting with acute stroke and contribute to overall morbidity and mortality. Prophylactic measures for the reduction of cardiac adverse events in hospitalized stroke patients have not been well understood. We sought to investigate the effect of early initiation of high-dose intravenous magnesium sulfate on cardiac adverse events in stroke patients.

methodsThis is a secondary analysis of the prehospital Field Administration of Stroke Therapy-Magnesium (FAST-MAG) randomized phase-3 clinical trial, conducted from 2005-2013. Consecutive patients with suspected acute stroke and a serum magnesium level within 72 hours of enrollment were selected. Twenty grams of magnesium sulfate or placebo was administered in the ambulance starting with a 15-minute loading dose intravenous infusion followed by a 24-hour maintenance infusion in the hospital.

resultsAmong 1126 patients included in the analysis of this study, 809 (71.8%) patients had ischemic stroke, 277 (24.6%) had hemorrhagic stroke, and 39 (3.5%) with stroke mimics. The mean age was 69.5 (SD13.4) and 42% were female. 565 (50.2%) received magnesium treatment, and 561 (49.8%) received placebo. 254 (22.6%) patients achieved the target, and 872 (77.4%) did not achieve the target, regardless of their treatment group. Among 1126 patients, 159 (14.1%) had at least one CAE. Treatment with magnesium was not associated with fewer cardiac adverse events. A multivariate binary logistic regression for predictors of CAEs showed a positive association of older age and frequency of CAEs (

conclusionTreatment of acute stroke patients with magnesium did not result in a reduction in the number or severity of cardiac serious adverse events.

Indexed as

HospitalizationAdministration, IntravenousAgedAged, 80 and overComorbidityDrug Administration ScheduleFemaleHeart DiseasesHumansIncidenceLos AngelesMagnesium SulfateMaleMiddle AgedRisk FactorsStrokeMagnesium Sulfate

Identifiers

PMID33072188
PMCPMC7533752
OpenAlexW3088212700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.